CORT News and Press, Corcept Therapeutics Incorporated From 11/06/23

2023-11-06 16:06:39 ET More on Corcept Therapeutics Corcept Therapeutics Incorporated (CORT) Q3 2023 Earnings Call Transcript Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade) Corcept Therapeutics Q3 2023 Earnings Preview Corcep...

2023-11-01 20:44:01 ET Corcept Therapeutics Incorporated (CORT) Q3 2023 Earnings Call Transcript November 01, 2023 05:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Off...

2023-11-01 16:28:19 ET More on Corcept Therapeutics Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade) Corcept Therapeutics Q3 2023 Earnings Preview Corcept Therapeutics plunges amid patent trial with Teva (update) Seeking Alpha&...

MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the horm...

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

Corcept Therapeutics Incorporated (CORT) is expected to report $0.22 for Q3 2023

2023-10-31 17:35:19 ET More on Corcept Therapeutics Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade) Corcept Therapeutics Incorporated (CORT) Q2 2023 Earnings Call Transcript Corcept Therapeutics plunges amid patent trial with Teva (up...

MENLO PARK, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the horm...

2023-10-10 21:41:26 ET Summary Amphastar Pharmaceuticals has implemented aggressive corporate strategies to maximize margins and increase sales, resulting in impressive EBIT and revenue growth. The company's focus on high-margin products and strategic acquisitions has contributed ...

2023-09-29 09:59:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...